Nanobiotix (NBTX) - Net Assets

Latest as of December 2025: $-84.48 Million USD

Based on the latest financial reports, Nanobiotix (NBTX) has net assets worth $-84.48 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($67.76 Million) and total liabilities ($152.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Nanobiotix's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$-84.48 Million
% of Total Assets	-124.68%
Annual Growth Rate	N/A
5-Year Change	-415.35%
10-Year Change	-585.58%
Growth Volatility	413.06

Nanobiotix - Net Assets Trend (2011–2025)

This chart illustrates how Nanobiotix's net assets have evolved over time, based on quarterly financial data. See Nanobiotix defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Nanobiotix (2011–2025)

The table below shows the annual net assets of Nanobiotix from 2011 to 2025. For live valuation and market cap data, see Nanobiotix (NBTX) market capitalisation.

Year	Net Assets	Change
2025-12-31	$-84.48 Million	-28.58%
2024-12-31	$-65.70 Million	-3463.07%
2023-12-31	$-1.84 Million	+93.18%
2022-12-31	$-27.05 Million	-200.95%
2021-12-31	$26.79 Million	-61.98%
2020-12-31	$70.47 Million	+3791.36%
2019-12-31	$-1.91 Million	-113.40%
2018-12-31	$14.24 Million	-67.57%
2017-12-31	$43.92 Million	+152.45%
2016-12-31	$17.40 Million	+11.45%
2015-12-31	$15.61 Million	-48.50%
2014-12-31	$30.32 Million	+852.78%
2013-12-31	$3.18 Million	-70.25%
2012-12-31	$10.70 Million	+1055.72%
2011-12-31	$925.53K	--

Equity Component Analysis

This analysis shows how different components contribute to Nanobiotix's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1871442200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	$1.45 Million	%
Other Comprehensive Income	$-376.14 Million	%
Other Components	$314.17 Million	%
Total Equity	$-84.48 Million	100.00%

Nanobiotix Competitors by Market Cap

The table below lists competitors of Nanobiotix ranked by their market capitalization.

Company	Market Cap
Omnicell Inc NASDAQ:OMCL	$1.75 Billion
Luoyang Xinqianglian Slewing Bearin SHE:300850	$1.75 Billion
Jamf Holding NASDAQ:JAMF	$1.75 Billion
Sunstone Hotel Investors Inc NYSE:SHO	$1.75 Billion
Kingsignal Technology Co Ltd SHE:300252	$1.75 Billion
Bumitama Agri Ltd F:2BU	$1.75 Billion
TSE Co. Ltd KQ:131290	$1.75 Billion
Formula Systems (1985) Ltd F:FSY	$1.75 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Nanobiotix's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -65,703,000 to -84,483,000, a change of -18,780,000.
Net loss of 23,961,000 reduced equity.
New share issuances of 1,535,000 increased equity.
Other comprehensive income decreased equity by 64,636,000.
Other factors increased equity by 68,282,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-23.96 Million	-28.36%
Share Issuances	$1.53 Million	+1.82%
Other Comprehensive Income	$-64.64 Million	-76.51%
Other Changes	$68.28 Million	+80.82%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares Nanobiotix's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	$0.60	$36.07	x
2012-12-31	$1.30	$36.07	x
2013-12-31	$0.30	$36.07	x
2014-12-31	$2.36	$36.07	x
2015-12-31	$1.10	$36.07	x
2016-12-31	$1.14	$36.07	x
2017-12-31	$2.51	$36.07	x
2018-12-31	$0.73	$36.07	x
2019-12-31	$-0.09	$36.07	x
2020-12-31	$2.89	$36.07	x
2021-12-31	$0.77	$36.07	x
2022-12-31	$-0.78	$36.07	x
2023-12-31	$-0.05	$36.07	x
2024-12-31	$-1.39	$36.07	x
2025-12-31	$-1.77	$36.07	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Nanobiotix utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -80.83%
• Asset Turnover: 0.44x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-108.97%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	-566.87%	-385.69%	0.47x	3.15x	$-5.34 Million
2012	-49.84%	-549.23%	0.07x	1.31x	$-6.40 Million
2013	-255.99%	-510.50%	0.21x	2.34x	$-8.46 Million
2014	-31.52%	-344.90%	0.07x	1.22x	$-12.59 Million
2015	-108.92%	-423.46%	0.15x	1.69x	$-18.56 Million
2016	-125.76%	-403.58%	0.18x	1.75x	$-23.62 Million
2017	-59.52%	-702.39%	0.06x	1.31x	$-30.54 Million
2018	-213.05%	-872.23%	0.08x	3.24x	$-31.77 Million
2019	0.00%	-2003.74%	0.05x	0.00x	$-50.72 Million
2020	-47.67%	-1444.73%	0.02x	1.90x	$-40.64 Million
2021	-175.45%	-1775.71%	0.03x	3.80x	$-49.68 Million
2022	0.00%	-1194.33%	0.08x	0.00x	$-54.34 Million
2023	0.00%	-109.64%	0.39x	0.00x	$-39.52 Million
2024	0.00%	0.00%	-0.11x	0.00x	$-61.56 Million
2025	0.00%	-80.83%	0.44x	0.00x	$-15.51 Million

Industry Comparison

This section compares Nanobiotix's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $155,285,360
Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Nanobiotix (NBTX)	$-84.48 Million	-566.87%	N/A	$1.75 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-34.80 Million	0.00%	0.00x	$83.17 Million
Abcellera Biologics Inc (ABCL)	$830.51 Million	14.32%	0.21x	$1.61 Billion
Abeona Therapeutics Inc (ABEO)	$-26.99 Million	0.00%	0.00x	$321.39 Million
Acumen Pharmaceuticals Inc (ABOS)	$266.97 Million	-19.62%	0.16x	$155.29 Million
Abpro Holdings, Inc. (ABP)	$3.07 Million	-479.81%	1.57x	$2.00 Million
Absci Corp (ABSI)	$179.13 Million	-57.56%	0.19x	$1.01 Billion
Arbutus Biopharma Corp (ABUS)	$182.50 Million	-46.25%	0.30x	$831.63 Million
ABVC Biopharma Inc (ABVC)	$4.59 Million	-357.76%	1.38x	$35.10 Million
Abivax SA American Depositary Shares (ABVX)	$33.94 Million	-14.97%	0.12x	$7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$113.93 Million	-49.49%	0.18x	$3.66 Billion

About Nanobiotix

NASDAQ:NBTX USA Biotechnology

Market Cap

$1.75 Billion

Market Cap Rank

#6753 Global

#2037 in USA

Share Price

$36.07

Change (1 day)

+0.22%

52-Week Range

$4.41 - $55.07

All Time High

$55.07